Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy. The main questions this study aims to answer are: * Can the NEO-Match® test predict how patients respond to neoadjuvant (pre-surgical) treatment for pancreatic cancer? * How well does the NEO-Match® test detect malignant pancreatic lesions compared to standard histopathological assessment? This is a prospective, single-arm study

Trial Details

NCT ID

NCT07542041

Phase

NA

Sponsor

ARTIDIS AG

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• ARTIDIS ART-1 Device

Locations (sample)

• Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

• Age ≥ 18 years
• Ability to understand and willingness to sign a written informed consent form
• Clinical indication for fine needle biopsy (FNB) of a suspicious pancreatic lesion accessible for biopsy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →